Literature DB >> 10414233

Expression of exon v6-containing CD44 isoforms is related to poor prognosis of acute myelocytic leukemia.

A Yokota1, G Ishii, Y Sugaya, M Nishimura, Y Saito, K Harigaya.   

Abstract

CD44 is a cell surface glycoprotein with a number of isoforms generated by alternative splicing of ten 'variant' exons in humans. Variant exon 6-containing isoforms of CD44 (CD44v6) have been implicated in the metastatic potential of rat carcinoma cell lines. Human homologues of CD44v6 are expressed in several tumour types and are involved in their progression. In the present study, we examined the expression of CD44 mRNA in 20 acute myelocytic leukemias by semiquantitative RT-PCR analysis and assessed its prognostic value. In all leukemic cells the predominant isoform was the 'standard' form of CD44 (CD44H), and intense bands were found in eight cases. CD44v6 was expressed in 11 cases, although its levels and those of other variants containing exon v7 through to v10 were much lower than those of CD44H. Isoforms containing exon v4 or v5 could not be detected. The expression of CD44v6 correlated with the death rate from leukemia (p > 0.05), but was not related to other risk factors. On the other hand, the intense expression of CD44H did not correlate with the prognosis of leukemia. CD44v6 thus appears to be a marker for the poor prognosis of acute myelocytic leukemia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10414233     DOI: 10.1002/(sici)1099-1069(199812)16:4<131::aid-hon631>3.0.co;2-k

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  2 in total

1.  CD44 ligation with A3D8 antibody induces apoptosis in acute myeloid leukemia cells through binding to CD44s and clustering lipid rafts.

Authors:  Hao Qian; Lijuan Xia; Peixue Ling; Samuel Waxman; Yongkui Jing
Journal:  Cancer Biol Ther       Date:  2012-08-16       Impact factor: 4.742

2.  The Constitutive Extracellular Protein Release by Acute Myeloid Leukemia Cells-A Proteomic Study of Patient Heterogeneity and Its Modulation by Mesenchymal Stromal Cells.

Authors:  Elise Aasebø; Annette K Brenner; Even Birkeland; Tor Henrik Anderson Tvedt; Frode Selheim; Frode S Berven; Øystein Bruserud
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.